Fidelis Capital Partners LLC Sells 297 Shares of Eli Lilly and Company (NYSE:LLY)

Fidelis Capital Partners LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,792 shares of the company’s stock after selling 297 shares during the quarter. Eli Lilly and Company makes up about 0.9% of Fidelis Capital Partners LLC’s holdings, making the stock its 24th largest position. Fidelis Capital Partners LLC’s holdings in Eli Lilly and Company were worth $7,055,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Tidemark LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $29,000. Core Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the second quarter valued at $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company in the second quarter worth $36,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $921.49 on Friday. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a market cap of $875.79 billion, a price-to-earnings ratio of 135.71, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a fifty day simple moving average of $895.06 and a two-hundred day simple moving average of $838.32.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were issued a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Citigroup started coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target for the company. Finally, BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the transaction, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 442,229 shares of company stock worth $410,002,456 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.